Published in Br J Clin Pharmacol on May 15, 2007
Morning melatonin serum values do not correlate with disease activity in rheumatoid arthritis: a cross-sectional study. Rheumatol Int (2014) 1.42
Melatonin: buffering the immune system. Int J Mol Sci (2013) 1.11
Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med (2008) 1.03
Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthritis Res Ther (2009) 0.95
The role of the circadian clock in rheumatoid arthritis. Arthritis Res Ther (2013) 0.95
Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment. Aging Dis (2011) 0.92
Therapeutic applications of melatonin. Ther Adv Endocrinol Metab (2013) 0.89
Melatonin treatment does not improve rheumatoid arthritis. Br J Clin Pharmacol (2008) 0.85
Evaluating the Oxidative Stress in Inflammation: Role of Melatonin. Int J Mol Sci (2015) 0.84
Clocking in: chronobiology in rheumatoid arthritis. Nat Rev Rheumatol (2015) 0.83
Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci (2013) 0.81
Melatonin attenuates clock gene cryptochrome1, which may aggravate mouse anti-type II collagen antibody-induced arthritis. Rheumatol Int (2010) 0.79
Serum melatonin levels in ankylosing spondilitis: correlation with disease activity. Rheumatol Int (2009) 0.78
Melatonin as an adjuvant therapy in patients with rheumatoid arthritis. Br J Clin Pharmacol (2008) 0.78
Melatonin: a novel indolamine in oral health and disease. Int J Dent (2012) 0.77
[Rheumatism, jet lag and the body clock]. Z Rheumatol (2011) 0.76
A Review of Melatonin, Its Receptors and Drugs. Eurasian J Med (2016) 0.76
Air Travel, Circadian Rhythms/Hormones, and Autoimmunity. Clin Rev Allergy Immunol (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Direct radioimmunoassay for melatonin in plasma. Clin Chem (1983) 1.69
Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int (2002) 1.42
A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res (1995) 1.36
Plasma total antioxidant capacity, lipid peroxidation, and erythrocyte antioxidant enzyme activities in patients with rheumatoid arthritis and osteoarthritis. Clin Biochem (2005) 1.35
Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem (2005) 1.31
Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation. Free Radic Biol Med (2000) 1.30
Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta (2003) 1.29
Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochem Funct (2003) 1.26
ICSH recommendations for measurement of erythrocyte sedimentation rate. International Council for Standardization in Haematology (Expert Panel on Blood Rheology) J Clin Pathol (1993) 1.20
Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci (2000) 1.16
Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J Rheumatol (2003) 1.15
Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J (1998) 1.14
Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J Chromatogr B Biomed Appl (1996) 1.13
Safety of melatonin in long-term use (?) J Biol Rhythms (1997) 1.10
Tryptophan metabolism and oxidative stress in patients with chronic brain injury. Eur J Neurol (2006) 1.08
Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharm Drug Dispos (2000) 1.07
Comparative analysis of the protective effects of melatonin and vitamin E on streptozocin-induced diabetes mellitus. J Pineal Res (2002) 1.05
Fluorimetric micro-determination of kynurenic acid, an endogenous blocker of neurotoxicity, by high-performance liquid chromatography. J Chromatogr (1988) 1.04
Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison. Ann Rheum Dis (2005) 1.04
Melatonin serum levels in rheumatoid arthritis. Ann N Y Acad Sci (2002) 1.02
The melatonin-cytokine connection in rheumatoid arthritis. Ann Rheum Dis (2005) 0.99
Tryptophan loading induces oxidative stress. Free Radic Res (2004) 0.96
The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice. J Neuroimmunol (1992) 0.95
Melatonin in rheumatoid arthritis: synovial macrophages show melatonin receptors. Ann N Y Acad Sci (2002) 0.94
Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett (2004) 0.93
Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int (1999) 0.92
Reaction of melatonin and related indoles with hydroxyl radicals: EPR and spin trapping investigations. Free Radic Biol Med (1997) 0.91
Melatonin influences interleukin-12 and nitric oxide production by primary cultures of rheumatoid synovial macrophages and THP-1 cells. Ann N Y Acad Sci (1999) 0.90
Case-control study of evening melatonin concentration in primary insomnia. BMJ (1996) 0.88
Melatonin in rheumatoid arthritis: a disease-promoting and modulating hormone? Clin Exp Rheumatol (2003) 0.86
Antioxidants as adjuvant therapy in rheumatoid disease. A preliminary study. Arzneimittelforschung (2001) 0.86
Inhibitory effect of melatonin on production of IFN gamma or TNF alpha in peripheral blood mononuclear cells of some blood donors. J Pineal Res (1994) 0.85
Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. Adv Exp Med Biol (2003) 0.85
Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol (2003) 0.85
Melatonin modulates mesenteric blood flow and TNFalpha concentrations after lipopolysaccharide challenge. Eur J Surg (2000) 0.84
Neutrophils as a specific target for melatonin and kynuramines: effects on cytokine release. J Neuroimmunol (2004) 0.84
Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury. J Neurochem (2006) 0.84
Melatonin blocks in vitro generation of prostaglandin by the uterus and hypothalamus. Eur J Pharmacol (1980) 0.83
N-acetyl-5-methoxy kynurenamine, a brain metabolite of melatonin, is a potent inhibitor of prostaglandin biosynthesis. Biochem Biophys Res Commun (1984) 0.83
Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci (1994) 0.82
Oxidative stress induced by phenylketonuria in the rat: Prevention by melatonin, vitamin E, and vitamin C. J Neurosci Res (2002) 0.81
Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology (1995) 0.81
Assessment of melatonin's ability to regulate cytokine production by macrophage and microglia cell types. J Neuroimmunol (2001) 0.81
Oxidative DNA damage induced by a melatonin metabolite, 6-hydroxymelatonin, via a unique non-o-quinone type of redox cycle. Biochem Pharmacol (2004) 0.80
Melatonin levels are decreased in rheumatoid arthritis. J Basic Clin Physiol Pharmacol (1992) 0.80
A novel role for melatonin: regulation of the expression of cell adhesion molecules in the rat hippocampus and cortex. Neurosci Lett (2002) 0.79
Melatonin increases interleukin-1beta and decreases tumor necrosis factor alpha in the brain of mice infected with the Venezuelan equine encephalomyelitis virus. Neurochem Res (2003) 0.78
Pinealectomy ameliorates collagen II-induced arthritis in mice. Clin Exp Immunol (1993) 0.78
Effect of melatonin on activated macrophage TNF, IL-6, and reactive oxygen intermediates. Shock (1998) 0.78
Melatonin, 5-methoxytryptamine and some of their analogs as cyclo-oxygenase inhibitors in rat medial basal hypothalamus. Brain Res (1987) 0.77
Melatonin inhibits prostaglandin E release from the medial basal hypothalamus of pinealectomized rats. J Pineal Res (1984) 0.77
Daytime 50 Hz magnetic field exposure and plasma melatonin and urinary 6-sulfatoxymelatonin concentration profiles in humans. J Pineal Res (2001) 0.77
Modulation of cytokine production from TH2-lymphocytes and monocytes by the pineal neurohormone melatonin. Oncol Rep (1996) 0.77
Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov (2002) 2.61
An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci (2012) 1.29
Hydrogen peroxide-induced oxidative stress in MC3T3-E1 cells: The effects of glutamate and protection by purines. Bone (2006) 1.21
Restored plasticity in a mouse model of neurofibromatosis type 1 via inhibition of hyperactive ERK and CREB. Eur J Neurosci (2007) 1.10
Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect Immun (2005) 1.09
Tryptophan metabolites and brain disorders. Clin Chem Lab Med (2003) 1.05
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol (2013) 1.04
Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis. Brain (2009) 1.02
Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J (2012) 1.00
Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment. Clin Exp Pharmacol Physiol (2006) 0.98
Electrochemical and in vitro evaluation of the redox-properties of kynurenine species. Biochem Biophys Res Commun (2003) 0.96
Selective subunit antagonists suggest an inhibitory relationship between NR2B and NR2A-subunit containing N-methyl-D: -aspartate receptors in hippocampal slices. Exp Brain Res (2004) 0.94
Responses of differentiated MC3T3-E1 osteoblast-like cells to reactive oxygen species. Eur J Pharmacol (2008) 0.94
Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease. Adv Exp Med Biol (2003) 0.94
A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. J Neurosci (2010) 0.93
New advances in the rehabilitation of CNS diseases applying rTMS. Expert Rev Neurother (2007) 0.91
Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring. Mol Brain (2012) 0.88
Involvement of kynurenines in Huntington's disease and stroke-induced brain damage. J Neural Transm (Vienna) (2011) 0.88
On the Biological Importance of the 3-hydroxyanthranilic Acid: Anthranilic Acid Ratio. Int J Tryptophan Res (2010) 0.88
Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clin Exp Pharmacol Physiol (2008) 0.86
Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. Adv Exp Med Biol (2003) 0.85
Preconditioning with 4-aminopyridine protects cerebellar granule neurons against excitotoxicity. Brain Res (2009) 0.84
Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease. J Neurochem (2009) 0.84
Adenosine receptor ligands protect against a combination of apoptotic and necrotic cell death in cerebellar granule neurons. Exp Brain Res (2007) 0.84
Kynurenine metabolism predicts cognitive function in patients following cardiac bypass and thoracic surgery. J Neurochem (2011) 0.84
Purine, kynurenine, neopterin and lipid peroxidation levels in inflammatory bowel disease. J Biomed Sci (2002) 0.84
5-Hydroxyanthranilic acid, a tryptophan metabolite, generates oxidative stress and neuronal death via p38 activation in cultured cerebellar granule neurones. Neurotox Res (2009) 0.83
Hydrogen peroxide mediates damage by xanthine and xanthine oxidase in cerebellar granule neuronal cultures. Neurosci Lett (2007) 0.82
Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus. Brain Res (2013) 0.82
Cell death in rat cerebellar granule neurons induced by hydrogen peroxide in vitro: mechanisms and protection by adenosine receptor ligands. Brain Res (2006) 0.82
NMDA-induced preconditioning attenuates synaptic plasticity in the rat hippocampus. Brain Res (2006) 0.81
Glutamate-induced depression of EPSP-spike coupling in rat hippocampal CA1 neurons and modulation by adenosine receptors. Eur J Neurosci (2010) 0.81
Prolonged exposures of cerebellar granule neurons to S-nitroso-N-acetylpenicillamine (SNAP) induce neuronal damage independently of peroxynitrite. Brain Res (2008) 0.80
Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole. Rheumatol Int (2006) 0.79
Altered apoptotic responses in neurons lacking RhoB GTPase. Eur J Neurosci (2011) 0.79
Gardening with Huntington's disease clients--creating a programme of winter activities. Disabil Rehabil (2010) 0.78
Resistance to kynurenic acid of the NMDA receptor-dependent toxicity of 3-nitropropionic acid and cyanide in cerebellar granule neurons. Brain Res (2008) 0.78
Prenatal inhibition of the kynurenine pathway leads to structural changes in the hippocampus of adult rat offspring. Eur J Neurosci (2014) 0.78
Memory impairment in rats by hippocampal administration of the serine protease subtilisin. Behav Brain Res (2010) 0.77
Preconditioning with NMDA protects against toxicity of 3-nitropropionic acid or glutamate in cultured cerebellar granule neurons. Neurosci Lett (2008) 0.77
AMPA receptor activation reduces epileptiform activity in the rat neocortex. Brain Res (2007) 0.77
A novel dihydro-pyrazolo(3,4d)(1,2,4)triazolo(1,5a)pyrimidin-4-one (AJ23) is an antagonist at adenosine A(1) receptors and enhances consolidation of step-down avoidance. Behav Brain Res (2012) 0.76
Group S8A serine proteases, including a novel enzyme cadeprin, induce long-lasting, metabotropic glutamate receptor-dependent synaptic depression in rat hippocampal slices. Eur J Neurosci (2007) 0.76
Adenosine preconditions against ouabain but not against glutamate on CA1-evoked potentials in rat hippocampal slices. Eur J Neurosci (2008) 0.76
Xanthine oxidase-induced neuronal death via the oxidation of NADH: prevention by micromolar EDTA. Brain Res (2009) 0.76
Protection by the flavonoids quercetin and luteolin against peroxide- or menadione-induced oxidative stress in MC3T3-E1 osteoblast cells. Nat Prod Res (2014) 0.76
Effects of AMPA and clomethiazole on spreading depression cycles in the rat neocortex in vivo. Eur J Pharmacol (2010) 0.76
Interactions between adenosine and metabotropic glutamate receptors in the rat hippocampal slice. Br J Pharmacol (2003) 0.76
LTP-induced depression of response to hypoxia in hippocampus: effects of adenosine receptor activation. Neuroreport (2003) 0.75
Neuroprotective role of learning in dementia: a biological explanation. J Alzheimers Dis (2003) 0.75
The mechanism of inhibition by xanthine of adenosine A1-receptor responses in rat hippocampus. Neurosci Lett (2004) 0.75
Differential effects of remacemide and desglycinyl-remacemide on epileptiform burst firing in the rat hippocampal slice. Neurosci Lett (2002) 0.75
Prenatal activation of maternal TLR3 receptors by viral-mimetic poly(I:C) modifies GluN2B expression in embryos and sonic hedgehog in offspring in the absence of kynurenine pathway activation. Immunopharmacol Immunotoxicol (2013) 0.75
Molecular changes associated with hippocampal long-lasting depression induced by the serine protease subtilisin-A. Eur J Neurosci (2011) 0.75
Blockade of presynaptic adenosine A1 receptor responses by nitric oxide and superoxide in rat hippocampus. Eur J Neurosci (2004) 0.75
Neuropeptide-containing cells in the cortex and striatum of mice with cerebral malaria. Adv Exp Med Biol (2003) 0.75
Long-term potentiation and adenosine sensitivity are unchanged in the AS/AGU protein kinase Cgamma-deficient rat. Neurosci Lett (2002) 0.75
Barium, glibenclamide and CGS21680 prevent adenosine A1 receptor changes of ES coupling and spike threshold. Neurosignals (2005) 0.75
Corrigendum: Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature (2017) 0.75
Effects of ethylenediamine in rodent models of seizure, motor coordination and anxiety. Brain Res (2012) 0.75
PEGs in chronic neurological disorders. Clin Med (2002) 0.75